4D Molecular Therapeutics (FDMT) Liabilities and Shareholders Equity (2019 - 2026)

4D Molecular Therapeutics (FDMT) has 8 years of Liabilities and Shareholders Equity data on file, last reported at $512.9 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $512.9 million, down 0.55% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.0 billion (down 14.04% YoY), and the FY2025 annual result was $566.7 million, up 1.13% from the prior year.
• Liabilities and Shareholders Equity fell to $512.9 million in Q1 2026 per FDMT's latest filing, from $566.7 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $629.9 million in Q1 2024 and troughed at $244.0 million in Q1 2023.
• A 5-year average of $433.8 million and a median of $424.0 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity soared 158.13% in 2024, then dropped 29.81% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $261.8 million in 2022, then climbed by 29.81% to $339.9 million in 2023, then soared by 64.87% to $560.4 million in 2024, then gained by 1.13% to $566.7 million in 2025, then dropped by 9.49% to $512.9 million in 2026.
• Business Quant data shows FDMT's Liabilities and Shareholders Equity at $512.9 million in Q1 2026, $566.7 million in Q4 2025, and $424.0 million in Q3 2025.